712 related articles for article (PubMed ID: 27291994)
1. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
[TBL] [Abstract][Full Text] [Related]
2. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
[TBL] [Abstract][Full Text] [Related]
3. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.
Mancardi GL; Sormani MP; Gualandi F; Saiz A; Carreras E; Merelli E; Donelli A; Lugaresi A; Di Bartolomeo P; Rottoli MR; Rambaldi A; Amato MP; Massacesi L; Di Gioia M; Vuolo L; Currò D; Roccatagliata L; Filippi M; Aguglia U; Iacopino P; Farge D; Saccardi R; ;
Neurology; 2015 Mar; 84(10):981-8. PubMed ID: 25672923
[TBL] [Abstract][Full Text] [Related]
4. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
[TBL] [Abstract][Full Text] [Related]
5. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
[TBL] [Abstract][Full Text] [Related]
6. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
[TBL] [Abstract][Full Text] [Related]
8. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis.
Samijn JP; te Boekhorst PA; Mondria T; van Doorn PA; Flach HZ; van der Meché FG; Cornelissen J; Hop WC; Löwenberg B; Hintzen RQ
J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):46-50. PubMed ID: 16361591
[TBL] [Abstract][Full Text] [Related]
9. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
10. [Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis].
Saiz A; Blanco Y; Berenguer J; Gómez-Choco M; Carreras E; Arbizu T; Graus F
Neurologia; 2008 Sep; 23(7):405-7. PubMed ID: 18726717
[TBL] [Abstract][Full Text] [Related]
11. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
Mancardi GL; Sormani MP; Di Gioia M; Vuolo L; Gualandi F; Amato MP; Capello E; Currò D; Uccelli A; Bertolotto A; Gasperini C; Lugaresi A; Merelli E; Meucci G; Motti L; Tola MR; Scarpini E; Repice AM; Massacesi L; Saccardi R;
Mult Scler; 2012 Jun; 18(6):835-42. PubMed ID: 22127896
[TBL] [Abstract][Full Text] [Related]
12. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
13. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
[TBL] [Abstract][Full Text] [Related]
14. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stüve O; Arnold DL; Spychala ME; McConville KC; Harris KM; Phippard D; Georges GE; Wundes A; Kraft GH; Bowen JD
JAMA Neurol; 2015 Feb; 72(2):159-69. PubMed ID: 25546364
[TBL] [Abstract][Full Text] [Related]
15. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis.
Burt RK; Oliveira MC; Shah SJ; Moraes DA; Simoes B; Gheorghiade M; Schroeder J; Ruderman E; Farge D; Chai ZJ; Marjanovic Z; Jain S; Morgan A; Milanetti F; Han X; Jovanovic B; Helenowski IB; Voltarelli J
Lancet; 2013 Mar; 381(9872):1116-24. PubMed ID: 23363664
[TBL] [Abstract][Full Text] [Related]
16. Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
Lee H; Nakamura K; Narayanan S; Brown R; Chen J; Atkins HL; Freedman MS; Arnold DL
Mult Scler; 2018 Jul; 24(8):1055-1066. PubMed ID: 28617152
[TBL] [Abstract][Full Text] [Related]
17. Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis.
Lee H; Narayanan S; Brown RA; Chen JT; Atkins HL; Freedman MS; Arnold DL
Mult Scler; 2017 Mar; 23(3):420-431. PubMed ID: 27246142
[TBL] [Abstract][Full Text] [Related]
18. Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.
Bose G; Atkins HL; Bowman M; Freedman MS
Mult Scler; 2019 Nov; 25(13):1764-1772. PubMed ID: 30251913
[TBL] [Abstract][Full Text] [Related]
19. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience.
Krasulová E; Trneny M; Kozák T; Vacková B; Pohlreich D; Kemlink D; Kobylka P; Kovárová I; Lhotáková P; Havrdová E
Mult Scler; 2010 Jun; 16(6):685-93. PubMed ID: 20350962
[TBL] [Abstract][Full Text] [Related]
20. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
Das J; Snowden JA; Burman J; Freedman MS; Atkins H; Bowman M; Burt RK; Saccardi R; Innocenti C; Mistry S; Laud PJ; Jessop H; Sharrack B
Mult Scler; 2021 Jul; 27(8):1198-1204. PubMed ID: 33565902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
